Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 5/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24673619 | 0.95 | GNAO1 (0.43) | GNAO1GNAI3GNAI1HRH3EPHX1 | |
| SCHEMBL21025868 | 0.86 | CYP2D6 (0.40) | GNAO1GNAI3GNAI1HRH3MAOB | |
| SCHEMBL23695901 | 0.84 | KDM1A (0.32) | GNAO1GNAI3GNAI1HRH3 | |
| SCHEMBL23696220 | 0.84 | PRMT6 (0.36) | GNAO1GNAI3GNAI1HRH3MAOB | |
| SCHEMBL22790840 | 0.83 | GNAI3 (0.44) | GNAO1GNAI3GNAI1HRH3EPHX1 | |
| SCHEMBL25592083 | 0.81 | GNAI3 (0.43) | GNAO1GNAI3GNAI1HRH3EPHX1 | |
| SCHEMBL25827075 | 0.81 | GNAI3 (0.43) | GNAO1GNAI3GNAI1HRH3EPHX1 | |
| SCHEMBL18591791 | 0.81 | GBA2 (0.34) | GNAO1GNAI3GNAI1HRH3MAOB | |
| SCHEMBL23696201 | 0.80 | KDM4E (0.32) | — | |
| SCHEMBL25727621 | 0.80 | KDM4E (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | GNAO1 2977/4885GNAI3 1664/4885GNAI1 1458/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | GNAO1 2977/4885GNAI3 1664/4885GNAI1 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.